Research Roundup

Debbie Rigby 01/07/2025

Debbie Rigby rounds up the latest in research news Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype In the MATINEE trial, treatment with mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), led to a 21% lower annualized rate of moderate or severe exacerbations when added to background triple inhaled therapy among patients

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Research Roundup

Previous Butler open to pharmacy vaping reforms

Next National Pharmacies appoints new CEO

MENU

ajp.com.au

Previous Butler open to pharmacy vaping reforms

Next National Pharmacies appoints new CEO

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.